Percutaneous edge‐to‐edge repair for common atrioventricular valve regurgitation in a patient with heterotaxy syndrome, single ventricle physiology, and unbalanced atrioventricular septal defect

Tan, Weiyi; Press, Marcella Calfon; Lluri, Gentian; Aboulhosn, Jamil

doi:10.1002/ccd.28782

Cited by 9 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[106][107][108] The use of MitraClips (Abbott Laboratories) has been established as an effective therapy in adult patients with primary and secondary mitral valve regurgitation 107,108 but has also been demonstrated to be effective in a select group of patients with CHD, mainly those with systemic atrioventricular valves (D-TGA Q27 and atrial switch or those with congenitally corrected TGA with systemic TR) or a common atrioventricular valve. 109,110 Experience with this technology is still limited in the congenital space, and the procedure can be technically challenging, especially given the differences in anatomy and the need for excellent transesophageal echocardiographic images to guide the intervention. 111 There have been <25 cases reported in the literature so far.…”

Section: Percutaneous Repair Of Native Atrioventricular Valve Regurgi...mentioning

confidence: 99%

Transcatheter Interventions in Patients With Adult Congenital Heart Disease

Tan¹,

Schmidt²,

Horlick³

et al. 2022

Journal of the Society for Cardiovascular Angiography & Int

Self Cite

View full text Add to dashboard Cite

Section: Percutaneous Repair Of Native Atrioventricular Valve Regurgi...mentioning

confidence: 99%

Transcatheter Interventions in Patients With Adult Congenital Heart Disease

Tan¹,

Schmidt²,

Horlick³

et al. 2022

Journal of the Society for Cardiovascular Angiography & Int

Self Cite

View full text Add to dashboard Cite

“…Although MitraClip has been shown to be a reliable and acceptable option for mitral valve repair in acquired mitral valve regurgitation, the use of such technology in tricuspid valve regurgitation is being explored more and more. Although the use of such transcatheter approach in ACHD patient population is limited to case reports, early results are promising, and it certainly will pave the way for new therapeutic interventional options [23].…”

Section: Failing Systemic Right Ventriclementioning

confidence: 99%

The systemic right ventricle in adult congenital heart disease: why is it still such a challenge and is there any hope on the horizon?

Lluri

Aboulhosn²

2021

Current Opinion in Cardiology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewAdult congenital heart disease patients with systemic right ventricle comprise a distinctly clinically challenging group of patients with increased morbidity and mortality. This article aims to review the different subgroups, most common complications and different treatment strategies Recent findingsMost commons long-term complications include heart failure and arrhythmias. Heart failure medical therapy treatments include several new agents, which show promise in systemic right ventricle patients. In addition, interventional therapies to mitigate atrioventricular valve regurgitation, baffle/conduit stenosis are discussed. Furthermore, several electrophysiological approaches to manage tachyarrhythmias as well as bradycardias are discussed. There is ongoing excitement on the new medical as well as interventional therapies that could provide benefit in additional to standard goal-directed medical therapy. SummaryThere is an array of medications as well as interventions aimed to treat patients with systemic right ventricle with limited benefits. A multidisciplinary approach with a prudent combination of such therapies to maximize benefit is imperative. This article reviews the data supporting such therapies.

show abstract

Percutaneous mitral valve repair in adults with congenital heart disease: Report of the first case‐series

Alshawabkeh

Mahmud

Reeves

2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background Systemic atrioventricular valve regurgitation (AVVR) is frequently encountered in adults with congenital heart disease (CHD). Surgical intervention is the mainstay of therapy, but in a specific high‐risk subset, percutaneous valve repair might offer a lower‐risk alternative. Methods Three patients with complex CHD and severe symptomatic AVVR underwent percutaneous mitral valve repair at a single center. All were deemed to be high‐risk for surgery by a multidisciplinary CHD team and provided informed consent for the compassionate use of the MitraClip (Abbott, Santa Clara, CA). Three‐dimensional heart models were generated for the procedure, which was performed by an adult CHD cardiologist (who provided imaging support) and an interventional cardiologist with expertise in CHD and percutaneous mitral valve repair. Results The first case was a 39 year‐old‐woman with [S,L,D] dextrocardia, double outlet right ventricle, mild tricuspid hypoplasia, and a secundum atrial septal defect, who was palliated at age 35 with a right bidirectional Glenn and later developed severe, symptomatic mitral regurgitation, and underwent placement of one MitraClip XTR device. Two patients with L‐loop transposition of the great arteries each successfully underwent placement of two MitraClip XTR devices; one patient had a single‐leaflet detachment of one of the clips with no change in regurgitation or clip position on follow‐up. All patients had significant reduction of AVVR and improvement in NYHA functional class. Conclusions Percutaneous atrioventricular valve repair in adults with CHD is feasible with the MitraClip but requires significant preprocedural planning and a multidisciplinary team that combines CHD and interventional therapeutic expertise.

show abstract

Percutaneous edge‐to‐edge repair for common atrioventricular valve regurgitation in a patient with heterotaxy syndrome, single ventricle physiology, and unbalanced atrioventricular septal defect

Cited by 9 publications

References 14 publications

Transcatheter Interventions in Patients With Adult Congenital Heart Disease

Transcatheter Interventions in Patients With Adult Congenital Heart Disease

The systemic right ventricle in adult congenital heart disease: why is it still such a challenge and is there any hope on the horizon?

Percutaneous mitral valve repair in adults with congenital heart disease: Report of the first case‐series

Contact Info

Product

Resources

About